Literature DB >> 3280573

Renal dysfunction following high-dose carboplatin treatment.

P O Mulder1, D T Sleijfer, E G de Vries, D R Uges, N H Mulder.   

Abstract

A case history is reported or renal failure during and after treatment with carboplatin for 3 days, total dose 750 mg/m2, in a conditioning regimen prior to autologous bone marrow transplantation. Pretreatment renal function was compromised after nephrectomy and chemotherapy with cisplatin. A decrease in glomerular filtration rate concurred with a decrease in excretion of platinum in the urine and an increase in urinary beta 2 microglobulin. Treatment with high-dose carboplatin in patients with impaired renal function and previous treatment with cisplatin may lead to further loss of renal function.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280573     DOI: 10.1007/bf00417840

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  16 in total

1.  High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study.

Authors:  M E Gore; A H Calvert; L E Smith
Journal:  Eur J Cancer Clin Oncol       Date:  1987-09

2.  Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry.

Authors:  A F LeRoy; M L Wehling; H L Sponseller; W S Friauf; R E Solomon; R L Dedrick; C L Litterst; T E Gram; A M Guarino; D A Becker
Journal:  Biochem Med       Date:  1977-10

3.  Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion.

Authors:  J M Koeller; D L Trump; K D Tutsch; R H Earhart; T E Davis; D C Tormey
Journal:  Cancer       Date:  1986-01-15       Impact factor: 6.860

4.  Whither carboplatin?--A replacement for or an alternative to cisplatin?

Authors:  D D Von Hoff
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

Review 5.  Carboplatin: the clinical spectrum to date.

Authors:  R Canetta; M Rozencweig; S K Carter
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

6.  High-performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urine.

Authors:  R C Gaver; G Deeb
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.

Authors:  S J Harland; D R Newell; Z H Siddik; R Chadwick; A H Calvert; K R Harrap
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

8.  Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; A C Jones; T J McElwain; S Raju; E Wiltshaw; I E Smith; J M Baker; M J Peckham; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  TNO-6-induced acute renal failure. A case report.

Authors:  J J Offerman; H Hollema; J D Elema; H Schraffordt Koops; E G de Vries
Journal:  Cancer       Date:  1985-10-01       Impact factor: 6.860

10.  Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.

Authors:  B D Evans; K S Raju; A H Calvert; S J Harland; E Wiltshaw
Journal:  Cancer Treat Rep       Date:  1983-11
View more
  2 in total

Review 1.  Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer.

Authors:  A J Wagstaff; A Ward; P Benfield; R C Heel
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

2.  Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.

Authors:  P O Mulder; E G de Vries; D R Uges; A H Scaf; D T Sleijfer; N H Mulder
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.